59.22
0.31 (0.52%)
| Previous Close | 58.91 |
| Open | 58.99 |
| Volume | 305,268 |
| Avg. Volume (3M) | 1,670,395 |
| Market Cap | 10,748,232,704 |
| Price / Earnings (Forward) | 5.00 |
| Price / Sales | 2.58 |
| Price / Book | 3.23 |
| 52 Weeks Range | |
| Earnings Date | 7 Feb 2025 - 11 Feb 2025 |
| Profit Margin | -9.34% |
| Operating Margin (TTM) | -6.94% |
| Diluted EPS (TTM) | -2.28 |
| Quarterly Revenue Growth (YOY) | 4.20% |
| Total Debt/Equity (MRQ) | 139.67% |
| Current Ratio (MRQ) | 2.51 |
| Operating Cash Flow (TTM) | 399.00 M |
| Levered Free Cash Flow (TTM) | 364.50 M |
| Return on Assets (TTM) | -0.18% |
| Return on Equity (TTM) | -11.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Catalent, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.0 |
| Average | -0.50 |
|
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 87.89% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |